JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

485.23 2.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

468.71

Max

490.03

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
Winstmarge	-39.75
Werknemers	528
EBITDA	-68M -106M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+47.73% upside

Dividenden
By Dow Jones
Volgende Winsten	19 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.9B 11B
Vorige openingsprijs	482.97
Vorige sluitingsprijs	485.23

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 feb 2026, 17:25 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 feb 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 feb 2026, 23:43 UTC

Marktinformatie

Gold Falls on Possible Technical Correction -- Market Talk

9 feb 2026, 23:14 UTC

Marktinformatie

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 feb 2026, 22:29 UTC

Marktinformatie

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 feb 2026, 22:19 UTC

Marktinformatie

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 feb 2026, 22:08 UTC

Marktinformatie

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 feb 2026, 22:01 UTC

Winsten

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 feb 2026, 21:59 UTC

Winsten

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 feb 2026, 21:59 UTC

Winsten

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 feb 2026, 21:58 UTC

Winsten

Friedman Industries 3Q Sales $168M >FRD

9 feb 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

9 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 feb 2026, 21:48 UTC

Winsten

Friedman Industries 3Q EPS 43c >FRD

9 feb 2026, 21:17 UTC

Winsten

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 feb 2026, 21:13 UTC

Marktinformatie

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 feb 2026, 21:04 UTC

Winsten

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 feb 2026, 20:30 UTC

Marktinformatie

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 feb 2026, 20:02 UTC

Marktinformatie

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 feb 2026, 19:42 UTC

Marktinformatie

Japan's Yield Curve Expected to Flatten -- Market Talk

9 feb 2026, 19:31 UTC

Marktinformatie

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 feb 2026, 19:27 UTC

Marktinformatie

Gold Climbs Back Over $5,000/oz -- Market Talk

9 feb 2026, 19:05 UTC

Marktinformatie

Nike Returns to List of Hottest Brands -- Market Talk

9 feb 2026, 18:19 UTC

Marktinformatie

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 feb 2026, 17:41 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 feb 2026, 17:31 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 feb 2026, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

9 feb 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 feb 2026, 17:17 UTC

Marktinformatie

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 feb 2026, 17:16 UTC

Winsten

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

47.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 705.56 USD 47.73%

Hoogste 964 USD

Laagste 570 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.